Your Gut Bacteria May Be Quietly Protecting Your Heart

A common resident of the human gut may be quietly helping to protect arteries. Researchers found that Bacteroides uniformis, one of the gut bacteria living in the intestines of many people, produces pentadecanoic acid, a fatty acid that slowed artery plaque in mice by acting on the same liver enzyme that statin medicines target, as reported by Nature's news team.

The team, based at Sun Yat-sen University and Shenzhen Bay Laboratory, started by comparing gut microbes in stool samples from people with and without cardiovascular disease. One species stood out because it was often depleted in people living with heart disease, which raised a question the researchers then tested in animals: was the microbe helping to protect arteries, or simply more common in healthier people? Scientists have suspected for years that gut bacteria influence metabolic health, with disruptions linked to conditions including diabetes, liver disease and cardiovascular disease, but pinning down an exact mechanism has proved difficult.

What the Mouse Experiments Showed

To find out, the researchers gave live microbes to mice genetically prone to atherosclerosis, the progressive buildup of inflammatory plaque in artery walls, and fed the animals a high-fat diet. After twelve weeks, treated mice showed less plaque in their main arteries, with the reduction measuring about one-third compared with untreated animals. The dose also lowered total cholesterol and LDL, often called bad cholesterol, and reduced inflammatory immune cells entering artery walls, according to MedicalXpress coverage of the study.

The team then isolated the molecule behind the protection and gave it directly to a separate group of mice three times a week for eight weeks. In that test, plaque buildup fell by about half. Heat-killed microbes, by contrast, offered no such benefit, which pointed to a product of living gut bacteria rather than the cells themselves.

The Same Liver Target as Statins

Lab work showed the compound binds to and inhibits HMG-CoA reductase, an enzyme the liver uses to make cholesterol and the same target blocked by statins. As cholesterol production fell, liver cells increased their supply of LDL receptors, proteins that capture cholesterol-carrying particles from the bloodstream, so the organ both made less cholesterol and pulled more of it out of circulation.

Two checks strengthened the case. When researchers disabled production of those receptors in the mouse liver, neither the microbe nor the compound protected arteries. Engineered strains that made less of the molecule colonized the gut but offered substantially weaker protection. Atherosclerosis remains the leading cause of death worldwide, and statins are prescribed to hundreds of millions of people, yet the drugs alone do not bring cholesterol down enough in a large share of people with advanced heart disease, and some people cannot tolerate high doses.

What This Does Not Prove Yet

The human evidence so far is associational. The researchers examined blood and stool samples from more than two hundred donors and found that people with abnormally high blood lipids carried lower levels of the compound, while people with heart disease carried fewer genes in their gut bacteria for manufacturing it. That pattern is consistent with the animal results, but it cannot show that raising levels of the molecule would protect a person's arteries.

Other caveats matter. The experiments used only male mice, and human diets and gut communities could change the response. An earlier small trial in women with fatty liver disease found that adding the compound to a Mediterranean-style diet further reduced LDL cholesterol, while a later analysis of two long-running studies found no link between higher blood levels of the molecule and lower incidence of cardiovascular disease. The compound is already marketed as a heart-health supplement, yet clinical evidence for a heart benefit remains limited, according to cardiovascular specialist Ben Chen of Monash Victorian Heart Institute. A co-author also disclosed a pending patent covering the molecule's use against atherosclerosis, as noted in the published paper.

For readers, the takeaway is patience, not a shopping list. No finding here supports taking a supplement or trying to reseed the gut, and researchers say larger human trials must first establish whether supplying the compound, or encouraging gut bacteria to make more of it, could safely reduce artery disease. What the study does offer is a concrete mechanism linking gut bacteria to heart health, and a new direction for therapies that work with the gut rather than around it. Follow more coverage on the Health topic page, and keep up with the latest headlines on the GenZ NewZ homepage.